Dimensional Fund Advisors’s Design Therapeutics DSGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.15M Buy
727,567
+32,824
+5% +$454K ﹤0.01% 2311
2026
Q2
$10.1M Buy
694,743
+262,903
+61% +$3.28M ﹤0.01% 2299
2026
Q1
$4.59M Buy
431,840
+133,919
+45% +$1.36M ﹤0.01% 2522
2025
Q4
$2.8M Buy
297,921
+18,104
+6% +$142K ﹤0.01% 2667
2025
Q3
$2.11M Sell
279,817
-33,546
-11% -$168K ﹤0.01% 2754
2025
Q2
$1.06M Buy
313,363
+24,761
+9% +$92.7K ﹤0.01% 2877
2025
Q1
$1.11M Buy
288,602
+73,337
+34% +$350K ﹤0.01% 2861
2024
Q4
$1.33M Buy
215,265
+80,905
+60% +$468K ﹤0.01% 2872
2024
Q3
$723K Buy
134,360
+53,407
+66% +$251K ﹤0.01% 2964
2024
Q2
$271K Buy
80,953
+44,098
+120% +$172K ﹤0.01% 3119
2024
Q1
$149K Sell
36,855
-4,993
-12% -$13.3K ﹤0.01% 3220
2023
Q4
$111K Sell
41,848
-12,267
-23% -$28.1K ﹤0.01% 3269
2023
Q3
$128K Sell
54,115
-5,520
-9% -$25.7K ﹤0.01% 3289
2023
Q2
$375K Sell
59,635
-16,850
-22% -$103K ﹤0.01% 3126
2023
Q1
$441K Buy
+76,485
New +$572K ﹤0.01% 3056
2022
Q3
$2.16M Buy
128,872
+100,728
+358% +$2M ﹤0.01% 2696
2022
Q2
$394K Buy
+28,144
New +$380K ﹤0.01% 3117

Other funds holding DSGN

Dimensional Fund Advisors's DSGN Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Design Therapeutics (DSGN) stake by 4.7% in Q3 2026, buying an estimated $454K and bringing the position to 727,567 shares worth $9.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2311.

Dimensional Fund Advisors first reported a position in DSGN in Q2 2022 and has held it in 17 quarters since. The position peaked at $10.1M in Q2 2026. 96 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • Dimensional Fund Advisors held 727,567 shares of Design Therapeutics worth $9.15M as of Q3 2026.
  • Dimensional Fund Advisors bought 32,824 Design Therapeutics shares in Q3 2026, an estimated $454K.
  • Design Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2311 holding.
  • Dimensional Fund Advisors first reported a position in Design Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Dimensional Fund Advisors's Design Therapeutics position peaked at $10.1M in Q2 2026.
  • 96 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.